Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · December 06, 2023

Safety and Efficacy of Short Oral Regimens for the Treatment of Rifampicin-Resistant Tuberculosis

The Lancet Respiratory Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Respiratory Medicine
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial
Lancet Respir Med 2023 Nov 15;[EPub Ahead of Print], BT Nyang'wa, C Berry, E Kazounis, I Motta, N Parpieva, Z Tigay, R Moodliar, M Dodd, V Solodovnikova, I Liverko, S Rajaram, M Rassool, T McHugh, M Spigelman, DA Moore, K Ritmeijer, P du Cros, K Fielding

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading